45 related articles for article (PubMed ID: 7654033)
1. Advantage of combined treatment of CPT-11 and 5-fluorouracil.
Matsuoka H; Yano K; Takiguchi S; Kono A; Seo Y; Saito T; Tomoda H
Anticancer Res; 1995; 15(4):1447-52. PubMed ID: 7654033
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
[TBL] [Abstract][Full Text] [Related]
3. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
Inoue Y; Miki C; Watanabe H; Hiro J; Toiyama Y; Ojima E; Yanagi H; Kusunoki M
J Gastroenterol; 2006 Dec; 41(12):1149-57. PubMed ID: 17287894
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of CPT-11 and SN-38 for gastrointestinal and recurrent carcinomas cultured on contact-sensitive plates.
Matsuoka H; Furusawa M; Tomoda H; Seo Y; Kono A; Takeda S; Sato K
Anticancer Res; 1994; 14(2A):405-9. PubMed ID: 8017840
[TBL] [Abstract][Full Text] [Related]
5. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Mullany S; Svingen PA; Kaufmann SH; Erlichman C
Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
[TBL] [Abstract][Full Text] [Related]
6. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
Oguro M; Seki Y
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
[TBL] [Abstract][Full Text] [Related]
9. In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.
Bernacki RJ; Pera P; Gambacorta P; Brun Y; Greco WR
Ann N Y Acad Sci; 2000; 922():293-7. PubMed ID: 11193904
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Ozawa Y; Kusano K; Owa T; Yokoi A; Asada M; Yoshimatsu K
Cancer Chemother Pharmacol; 2012 May; 69(5):1353-62. PubMed ID: 22349812
[TBL] [Abstract][Full Text] [Related]
11. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR; Grivicich I; Peters GJ; Schwartsmann G
Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Aiba K; Funakoshi S; Mizunuma N; Dobashi N; Hirano A; Sano M; Kuraishi Y; Kamada M; Ohno N; Sugimoto Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1601-6. PubMed ID: 8060134
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of CPT-11 against a Taxol-resistant cell line.
Matsuoka H; Yano K; Takiguchi S; Wakasugi H; Tomoda H
Anticancer Res; 1997; 17(1A):467-71. PubMed ID: 9066696
[TBL] [Abstract][Full Text] [Related]
14. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
16. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Torigoe S; Ogata Y; Matono K; Shirouzu K
Anticancer Res; 2009 Jun; 29(6):2083-9. PubMed ID: 19528468
[TBL] [Abstract][Full Text] [Related]
18. In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Yamashita YT; Ohtsuka M; Sekizawa K
J Exp Ther Oncol; 2002; 2(1):42-6. PubMed ID: 12415619
[TBL] [Abstract][Full Text] [Related]
19. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
